<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03565146</url>
  </required_header>
  <id_info>
    <org_study_id>Focus-PiQo4 Pigmentation-17-01</org_study_id>
    <nct_id>NCT03565146</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of PiQo4 System for the Treatment of Pigmented Lesions</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of PiQo4 System for the Treatment of Pigmented Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Focus Medical, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Focus Medical, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of at least 25 healthy subjects at a single site, aged 21-70 years old with
      congenital or acquired challenging/resistant, age/sun-related flat and benign facial
      pigmentation with or without hand pigmentation who wish to improve their skin appearance.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 29, 2018</start_date>
  <completion_date type="Actual">June 5, 2019</completion_date>
  <primary_completion_date type="Actual">June 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pigmentation Improvement Scale</measure>
    <time_frame>1 month follow up</time_frame>
    <description>Facial Pigmentation Improvement evaluated by the investigator at the 1 month follow up visit compared to baseline using a 5-point improvement scale where a score of between 0 and 4 will be assigned (0-No improvement; 1- Trace to mild improvement of some lesions; 2- Moderate response: some lesions lighter; 3- Good response: most lesions much lighter; 4 - excellent response: most or all lesions are much lighter or gone)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pigmentation Improvement Scale</measure>
    <time_frame>3 month follow up</time_frame>
    <description>Facial Pigmentation Improvement evaluated by the investigator at the 3 month follow up visit compared to baseline using a 5-point improvement scale where a score of between 0 and 4 will be assigned (0-No improvement; 1- Trace to mild improvement of some lesions; 2- Moderate response: some lesions lighter; 3- Good response: most lesions much lighter; 4 - excellent response: most or all lesions are much lighter or gone)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Pigmentation</condition>
  <arm_group>
    <arm_group_label>Pigmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of Pigmented Lesions Using PiQo4 Laser System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PiQo4 Laser System</intervention_name>
    <description>PiQo4 Laser System for treatment of pigmented lesions</description>
    <arm_group_label>Pigmentation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy Female or Male

          2. Age= 21-70 (Adults)

          3. Fitzpatrick skin phototype = I-V

          4. Congenital or acquired benign pigmentation on face with optional pigmentation on hand.

          5. Presence of at least 4 lesions of similar pigmentation intensity in the treatment
             area, in diameters larger than 2 mm

          6. Able to read, understand and provide written Informed Consent

          7. Able and willing to comply with the treatment/follow-up schedule and requirements

          8. Women of child-bearing potential are required to use a reliable method of birth
             control (such as an intrauterine device, birth control pills, condom with spermicidal,
             NuvaRing, partner with vasectomy, Implanon or other FDA-approved devices, or
             abstinence) during the course of the study

          9. Willing to have digital photographs taken of the treatment area

         10. Willing to refrain from using any prescription or over the counter topical creams used
             for the treatment of pigmentation (e.g., hydroquinone, retinoids, and/or
             corticosteroids) in the treatment area during the study period.

         11. Willing to protect from sun exposure and use an approved sunscreen of SPF 30 or higher
             in the treatment area daily during the entire duration of the study, including the
             follow-up period.

         12. Agree not to undergo any other procedure(s) for the treatment of pigmentation or solar
             lentigines during the study.

        Exclusion Criteria:

          1. History of post inflammatory pigmentary disorders, particularly a tendency for hyper-
             or hypo-pigmentation

          2. Melasma

          3. Excessive underlying vascular conditions (e.g. dense network of capillaries)

          4. Pregnant, intending to become pregnant during the course of study, less than 3 months
             postpartum or less than 3 months after completion of breastfeeding

          5. Prior skin laser, light, or other energy device treatment in treated area within 6
             months of initial treatment or during the course of the study

          6. Prior ablative resurfacing procedure or face-lift in treated area with laser or other
             devices within 12 months of initial treatment or during the course of the study

          7. Prior treatment with medium-depth or deeper chemical peels or dermabrasion in treated
             area within 3 months of initial treatment or during the course of the study

          8. Prior use of any prescription or over the counter topical creams used for the
             treatment of pigmentation (e.g., hydroquinone, retinoids, and/or corticosteroids) in
             the treatment area within 3 months of initial treatment or during the course of the
             study

          9. Any other surgery in treated area within 9 months of initial treatment or during the
             course of the study

         10. Hypersensitive to light exposure or the use of photosensitive medication for which
             light exposure is contraindicated

         11. Multiple dysplastic nevi in area to be treated

         12. Significant concurrent illness (e.g. uncontrolled diabetes) or any disease state that
             in the opinion of the Investigator would interfere with the treatment or healing
             process

         13. Any dermal/epidermal damage or disorder, mainly vascular or textural lesions, in the
             treatment area.

         14. Any underlying tattoo in the treatment area.

         15. Unable or unlikely to refrain from tanning, including the use of tanning booths,
             during the course of the study

         16. Participation in a study of another investigational device or drug involving the same
             anatomical site within 3 months prior to enrollment or during this evaluation, or if
             not involving the same anatomical site, as per the Investigator's discretion

         17. History of keloid or any other type of hypertrophic scar formation or poor wound
             healing

         18. Signs and symptoms of hormonal disorders such as Melasma, as per the Investigator's
             discretion.

         19. Concurrent inflammatory skin conditions, open laceration, or abrasion of any sort on
             area to be treated during the course of treatment

         20. Active Herpes Simplex (perioral or facial) at the time of treatment or having
             experienced more than three episodes of Herpes Simplex eruption within a year of study
             enrollment

         21. Having a bleeding disorder or taking anticoagulation medications, including daily use
             of aspirin, in a manner which does not allow for a minimum 10 day washout period prior
             to treatment (as per the discretion of the subject's primary care physician)

         22. History of immunosuppression/immune deficiency disorders (including HIV infection or
             AIDS) or the use of immunosuppressive medications

         23. Having any form of active cancer at the time of enrollment and during the course of
             the study or history of skin cancer on the face/hands

         24. Pigmented lesions in the areas to be treated that are suspicious for pre-malignancy or
             malignancy and/or are not deemed suitable for phototherapy, as per the Investigator's
             discretion

         25. Unable to understand or provide written Informed Consent (e.g. mental incompetence or
             evidence of active substance abuse)

         26. Any condition that, in the Investigator's opinion, would make it unsafe (for the
             subject or for the study personnel) to treat the subject as part of this research
             study

         27. If undergoing punch biopsy, allergic to lidocaine or epinephrine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel P Friedmann</last_name>
    <role>Principal Investigator</role>
    <affiliation>Westlake Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Westlake Dermatology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 10, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>December 25, 2019</last_update_submitted>
  <last_update_submitted_qc>December 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

